Healthcare provider profile · identity verified

Carly Linick, PA-C

Physician Assistant · ITHACA, NY · NPI 1780148668

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	140	35
Atorvastatin Calcium	Atorvastatin Calcium	122	40
Rosuvastatin Calcium	Rosuvastatin Calcium	100	41
Lisinopril	Lisinopril	99	32
Amlodipine Besylate	Amlodipine Besylate	72	26
Losartan Potassium	Losartan Potassium	58	23
Metoprolol Succinate	Metoprolol Succinate	54	17
Fluoxetine Hcl	Fluoxetine Hcl	49	11
Omeprazole	Omeprazole	48	21
Metformin Hcl	Metformin Hcl	47	16
Montelukast Sodium	Montelukast Sodium	47	12
Simvastatin	Simvastatin	47	17
Hydrochlorothiazide	Hydrochlorothiazide	46	18
Gabapentin	Gabapentin	43	15
Sertraline Hcl	Sertraline Hcl	41	12
Trazodone Hcl	Trazodone Hcl	41	12
Eliquis	Apixaban	40	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	40	suppressed
Buspirone Hcl	Buspirone Hcl	39	suppressed
Famotidine	Famotidine	39	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	37	13
Azithromycin	Azithromycin	34	23
Bupropion Xl	Bupropion Hcl	33	suppressed
Metformin Hcl Er	Metformin Hcl	33	11
Pantoprazole Sodium	Pantoprazole Sodium	33	11
Mirtazapine	Mirtazapine	32	suppressed
Clonazepam	Clonazepam	29	19
Furosemide	Furosemide	27	suppressed
Alprazolam	Alprazolam	26	20
Warfarin Sodium	Warfarin Sodium	26	suppressed
Allopurinol	Allopurinol	23	suppressed
Carbamazepine Er	Carbamazepine	23	suppressed
Oxycodone Hcl	Oxycodone Hcl	23	12
Ozempic	Semaglutide	23	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	22	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Prednisone	Prednisone	20	13
Ramipril	Ramipril	20	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Lorazepam	Lorazepam	18	12
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	13
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	12
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	14
Glipizide Er	Glipizide	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	13
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	11
Metoprolol Tartrate	Metoprolol Tartrate	14	suppressed
Naproxen	Naproxen	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Topiramate	Topiramate	14	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Captopril	Captopril	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Diazepam	Diazepam	12	suppressed
Finasteride	Finasteride	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Fluticasone Propionate	Fluticasone Propionate	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Theophylline Er	Theophylline Anhydrous	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error